Ken Mills

Professor

  • Room 0G.011 - PGJCCR

    United Kingdom

Accepting PhD Students

PhD projects

There are opportunities to investigate molecular mechanisms in myeloid blood cancers including epigenetic alterations, DNA repair deficiency, altered signal pathways to identify therapeutic targets for novel agents or repurposed drugs using drug screens and/or NGS technologies to improve patient outcomes.

20012021

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Interests

My interests are in translational research in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) with the aim of improving diagnosis, prognosis and prediction of therapeutic responses. 

Research Statement

The molecular and cytogenetic abnormalities in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndromes (MDS) are increasingly well defined and these are being implicated in stratification for diagnosis and prognosis.

We have a series of studies being undertaken to identify repurposed therapies to target different sub-groups of adult and paediatric AML; the MuSICAL and the CaUSAL are funded by Leuka 

Alongside these, are studies introducing clinically relevant mutations using the CRISPR-Cas mechanism to produce isogenic cell lines to further understand the molecular disruption caused by the mutation.  Our recent direction of research has involved investigating the role of DNA repair in sub-cohorts of MDS and AML supported with grants from the LLNI, Leuka and MDS UK

Several studies are being undertaken in collaboration with previous members of the EU funded COST Action on translating genomic and epigenetic studies of MDS and AML (EuGESMA) with partners in 22 countries including Spain,  Denmark, Italy, Germany, Serbia and Finland.

Current funding is from the Leukaemia & Lymphoma NI (LLNI), Leuka, , Children’s Cancer and Leukaemia Group (CCLG)/Little Princess Trust, MDS UK and the Department of Education and Learning (DEL) and with recent funding from Cancer Research UK, Myeloma UKBloodwise, Queen's University Belfast, Cancer Research UK, and the R&D Division of the NI HSC.   The laboratory is  an associated member of the IMI2 funded HARMONY project and a full partner in a recently (2019) awarded Erasmus Plus Knowledge Exchange Network (Nehmesis)

Teaching

Acting Deputy Director:  Centre for Biomedical Science Education

Associate Director for Undergraduate Teaching (CCRCB)

Coordinator for the CCRCB Summer School Programme

Module coordinator for Molecular Markers of Disease (BMS3104)

Module coordinator for Pathobiology (BMS2023) and Cellular & Molecular Haematology (BMS3009)

Teaching contributions to BMS2023, BMS 2106, BMS3009, BMS3104

Module coordinator for SCM81821 and SCM7046 within both the MSc in Computational Biology and Bioinformatics and the MSc in Molecular Pathology

Achievements

Chair of the Northern Ireland council of the Royal College of Pathologists (2016-2019)

Member of the Manx Health and Bioscience Advisory Board (2017-2019)

REF Advisor for the School of Health Sciences, Liverpool Hope University (2016-2018)

Expertise related to UN SDGs

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Fingerprint

Dive into the research topics where Ken Mills is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 12 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or
If you made any changes in Pure these will be visible here soon.